Bronstein, Gewirtz & Grossman, LLC Files Class Action Lawsuit Against AstraZeneca PLC
On January 22, 2025, Bronstein, Gewirtz & Grossman, LLC, a leading national securities fraud law firm, announced the filing of a class action lawsuit against AstraZeneca PLC (“AstraZeneca” or “the Company”) (NASDAQ: AZN) and certain of its officers. The lawsuit was filed in the United States District Court for the Eastern District of New York and alleges violations of the federal securities laws.
Class Definition
The lawsuit seeks to recover damages on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca securities between February 23, 2022, and December 17, 2024 (the “Class Period”).
The complaint alleges that during the Class Period, AstraZeneca and its officers made false and misleading statements and failed to disclose material information regarding the Company’s financial condition and business operations. Specifically, the complaint alleges that the defendants failed to disclose that:
- AstraZeneca was experiencing declining sales of certain of its key drugs;
- The Company was facing increasing competition from generic and biosimilar versions of its drugs;
- AstraZeneca was experiencing manufacturing issues with certain drugs;
- The Company was experiencing delays in the development of new drugs;
- The Company was engaging in improper pricing practices;
As a result of these alleged false and misleading statements, AstraZeneca’s stock traded at artificially inflated prices during the Class Period, causing investors to sustain significant losses.
Impact on Individual Investors
If you purchased or otherwise acquired AstraZeneca securities during the Class Period, you may be eligible to recover your losses, including any losses from selling shares, by joining this class action lawsuit. You may also be able to seek recovery of any damages or losses that you have incurred as a result of the securities’ decline in value.
Impact on the World
The filing of this class action lawsuit against AstraZeneca could have significant implications for the pharmaceutical industry as a whole. It sends a clear message that investors will not tolerate misrepresentations or failures to disclose material information, and that companies must be transparent in their reporting. It also highlights the importance of rigorous research and analysis by investors, as well as the role of securities law firms in protecting investors’ rights.
Conclusion
The filing of this class action lawsuit against AstraZeneca is a reminder that companies and their officers must provide accurate and timely information to investors. It also underscores the importance of investors remaining vigilant and conducting thorough research before making investment decisions. If you believe that you may have lost money as a result of AstraZeneca’s alleged securities law violations, you may be eligible to join this class action lawsuit. For more information, please contact Bronstein, Gewirtz & Grossman, LLC.
Bronstein, Gewirtz & Grossman, LLC, with offices in New York, Nashville, and Los Angeles, is a leading securities litigation firm. Our lawyers have recovered billions of dollars for investors victimized by fraud. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:
Bronstein, Gewirtz & Grossman, LLC
212-697-1001
[email protected]
www.bgandg.com
